Adjusting linezolid for neuropathy doesn't harm TB treatment success

Peripheral neuropathy — numbness, tingling or pain in the hands and feet — is a common side effect during treatment for multidrug- or rifampicin-resistant tuberculosis and often forces doctors to reduce or pause a key antibiotic, linezolid. Those dose changes are a dilemma: clinicians want to protect patients from nerve damage but worry that weakening the drug regimen could undermine the chance of curing tuberculosis. To address that uncertainty, Matthew L. Romo and colleagues used a modern observational approach to compare what happened when clinicians changed linezolid soon after neuropathy appeared versus delaying a change or not changing the dose at all. Working with data from the endTB Observational Study, they focused on people who developed mild or moderate peripheral neuropathy while taking linezolid 600 mg daily within six months of starting an individualized regimen. The researchers set up a target trial emulation — a way to mimic a randomized trial using real-world data — and then compared three common management strategies: immediate change, deferred change, and no change, looking at how each affected overall treatment success.

To estimate the likely effects of these strategies, the team used a clone-censor-weight approach to produce an observational analog of the per-protocol effect on treatment success. They identified 303 eligible participants across 12 countries. Peripheral neuropathy appeared a median of 11 weeks after starting treatment (interquartile range 4–18 weeks). The investigators calculated weighted, standardized probabilities of treatment success under each strategy: immediate change had a probability of 85.8% (95% CI: 72.7%, 93.9%), deferred change 78.8% (95% CI: 66.1%, 87.1%), and no change 85.2% (95% CI: 80.5%, 89.1%). When compared directly with no change, the treatment success ratio for immediate change was 1.01 (95% CI: 0.86, 1.11) and for deferred change was 0.93 (95% CI: 0.78, 1.01). All analyses explicitly examined people receiving linezolid 600 mg daily as part of individualized regimens for multidrug- or rifampicin-resistant tuberculosis treatment.

The study did not find evidence that promptly modifying linezolid for mild or moderate peripheral neuropathy substantially reduced the chance of treatment success in the first six months of an individualized regimen. In other words, immediate dose reductions or temporary suspensions of linezolid — practices clinicians already use to manage non-severe nerve side effects — were not linked to worse overall outcomes in this analysis. These results support the clinical approach of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy, balancing side effect management against maintaining effective treatment. Because the analysis focused on mild or moderate neuropathy in the early months of therapy, the findings speak directly to that common clinical scenario and provide evidence to guide decision-making about whether and when to modify linezolid dosing.